Could a single injection replace biopsies for breast cancer?
NCT ID NCT05695859
First seen Jun 27, 2026 · Last updated Jun 27, 2026
Summary
This study tested a new imaging method that uses a radioactive tracer to detect HER2 protein in breast cancer tumors and nearby lymph nodes. 24 women with primary breast cancer received one injection followed by a scan. The goal was to see if the scan results matched standard tissue tests. If it works, this could offer a less invasive way to check HER2 status.
What this could mean
Our plain-language read of the trial. This is informational only — not medical advice or a prediction.
Active substance
Technetium-99m-labelled DARPinG3
What this could lead to
If successful, this imaging method could help doctors see HER2 levels in breast cancer tumors without needing a biopsy, making diagnosis faster and less invasive.
What could go wrong
This is a small, early study with only 24 participants, so results may not apply to everyone. The imaging accuracy needs to be confirmed in larger trials.
Disclaimer
Read more
Show less
This is a summary of
the original study
.
Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
This is a summary of the original study . Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for BREAST CANCER are added.
By submitting, you agree to our Terms of use
Conditions
The condition(s) this trial relates to.
As listed by the trial registrant
The condition terms exactly as the trial's registrant entered them.
Contacts and locations
Show contact details
Enter your email to view the contact information for this study.
By submitting, you agree to our Terms of use
Locations
-
Russia Tomsk NRMC
Tomsk, Russia